md-medicaldata

Authors

 

Sara Šekerović¹, Radmila Žeravica<sup>1,2

1</sup>Univerzitet u Novom Sadu, Medicinski fakultet
²Klinički centar Vojvodine, Centar za laboratorijsku medicinu - Odeljenje za nuklearnu medicinu, Novi Sad, Srbija

 

UDK: 616.447-073
616.441-008.61

The paper was received / Rad primljen: 01.03.2024.

Accepted / Rad prihvaćen: 21.03.2024.

 

Correspondence to:

Sara Šekerović
Univerzitet u Novom Sadu,
Medicinski fakultet Novi Sad, Srbija
Hajduk Veljkova 3, 21000, Novi Sad
e-mail: sara.sekerovic@gmail.com

 

 

Sažetak

 

 

Uvod: Primarni hiperparatireoidizam (PHPT) predstavlja jednu od najčešćih endokrinih bolesti. Većina pacijenata koji boluju od PHPT je asimptomatske prirode, dok manji procenat pacijenata je simptomatski, praćen povećanjem vrednosti kalcijuma. Studije ukazuju na to da normokalcemični primarni hiperparatireoidizam (NPHPT) može biti početni stadijum u razvoju konačnog, simptomatskog oblika PHPT-a. Rana dijagnoza PHPT-a je značajna u cilju prevencije mogućih komplikacija, a kao metoda izbora za detekciju hiperfunkcionih lezija se koristi dvofazna metoda 99mTc-MIBI paratiroidna scintigrafija. Cilj rada: Cilj studije jeste evaluacija uloge 99mTc-MIBI paratireoidne scintigrafije u detekciji lezija kod pacijenata sa NPHPT. Materijal i metode: Ispitivanje je sprovodeno kao retrospektivna analiza podataka iz medicinske dokumentacije pacijenata kod kojih je, u Centru za laboratorijsku medicinu, Odeljenju za nuklearnu medicinu, urađena scintigrafija paratireoidnih žlezdа, kao i laboratorijsko ispitivanje uzorka krvi u periodu  2021–2022. godine. Interpretacija scintigrafskih nalaza vršena je u konsenzusu od strane dvoje iskusnih specijalista nuklearne medicine. Rezultati: Od ukupnog broja ispitanika, njih 52 pripada normokalcemičnoj grupi, a preostalih 48 hiperkalcemičnoj grupi. Analizom rezultata je uočena statistička značajnost pri poređenju polne zastupljenosti između dve grupe (p=0,03). Pozitivan MIBI nalaz scintigrafije u normo­kal­cemičnoj grupi ima 27 pacijenata od ukupno 52, što iznosi 51,9%, dok u hiper­kal­cemi­čnoj 44 od 48 pacijenata ima pozitivan MIBI nalaz scintigrafije (91,6%). Zaključak: Rezultati studije ukazuju da više od polovine pacijenata (51,9%) sa normokalcemičnim primarnim hiperparatireoidizmom ima pozitivan nalaz paratiroidne scintigrafije što može ukazivati na značaj MIBI scintigrafije u ranoj detekciji lezije kod  pacijenata sa normokalcemičnim primarnim hiperparatireoidizmom..

 

Ključne reči:

kalcijum; primarni hiperparatiroidizam; 99mTc-MIBI paratiroidna scintigrafija

 

 

 

Abstract

 

Introduction: The majority of patients suffering from primary hyperparathyroidism (PHPT) are asymptomatic, while a percentage of patients are symptomatic. Studies suggest that normocalcemic primary hyperparathyroidism (NPHPT) may be the initial stage in the development of a symptomatic form of PHPT. Early diagnosis of PHPT is important to prevent possible complications, and the 99mTc-MIBI parathyroid scintigraphy is the method of choice for detecting hyper-functional lesions. The aim: The aim of the study is to evaluate the role of 99m-Tc-MIBI parathyroid scintigraphy in detecting lesions in patients with NPHPT. Material and methods: The study was conducted as a retrospective analysis of data from the medical records of patients who underwent scintigraphy of the parathyroid glands, as well as laboratory testing of blood samples in the period 2021-2022 at the Center for Laboratory Medicine, Department of Nuclear Medicine. The scintigraphic findings were interpreted in consensus by two experienced specialists in nuclear medicine. Results: Of the total number of patients, 52 belong to the normocalcemic group, and 48 belong to the hypercalcemic group. A positive MIBI scintigraphy finding in the normocalcemic group has 27 patients out of 52 (51.9%), while in the hypercalcemic group, 44 out of 48 patients have a positive MIBI scintigraphy finding (91.6%). Conclusion: The results of our study indicate that more than half of patients (51.9%) with normocalcemic primary hyperparathyroidism have a positive result of parathyroid scintigraphy, which may indicate the importance of MIBI scintigraphy in the early detection of lesions in patients with normocalcemic primary hyperparathyroidism.

 

Key words:

calcium; primary hyperparathyroidism; 99mTc–MIBI parathyroid scintigraphy

 

 

 

 

References:

1. Borota R, Ćurić N, Čabarkapa V, Dujmović F, Đerić M, Ilinčić B i dr. Osnovi kliničke patofiziologije. Četvrto izdanje. Novi Sad: Futura; 2020.
2. Pancirov M. Incidencija kirurški zbrinutih bolesnika oboljelih od primarnog hiperparatireo­idizma u Klinici za bolesti uha, nosa i grla s kirurgijom glave i vrata Kliničkog bolničkog centra Split u petogodišnjem razdoblju (od 2013. do 2017. godine) Diss. , University of Split. School of Medicine. Otorhinolaryngology. 2018.
3. Gungor S, Dede F, Can B, Keskin H, Aras M, Ones T et al. The value of parathyroid scintigraphy on lesion detection in patients with normocalcemic primary hyperparathyroidism. Rev Esp Med Nucl Imagen Mol (Engl Ed).2022;1;41(2):86-90.
4. 4.Bilezikian JP, Silverberg SJ. Normocalcemic primary hyperparathyroidism.
5. Arq Bras Endocrinol Metabol.2010;54:106-9.
6. 5.Díaz-Soto G, Julián MT, Puig-Domingo M. Normocalcemic primary hyperparathyroidism: a newly emerging disease needing therapeutic intervention. Hormones. 2012;11:390-6.
7. Mazokopakis EE, Skarakis SN. Investigating patients with normocalcemic hyperparathyroidism: When is a parathyroid scintigraphy indicated?.
8. World J Nucl Med.  2019;18(03):227-31.
9. Cusano NE, Cipriani C, Bilezikian JP. Management of normocalcemic primary hyperparathyroidism. Best Pract Res Clin Endocrinol Metab. 2018;32(6):837-45.
10. Sanadgol H, Ardalan MR, Tamadon MR, Mardani S, Nasri H. Current concepts on normocalcemic primary hyperparathyroidism. J Parathyr Dis. 2013;1:21-3.
11. Souberbielle JC, Cavalier E, Cormier C. How to manage an isolated elevated PTH?.
12. Ann Endocrinol (Paris). 2015;134-141.
13. Cordellat IM. Hyperparathiroidism: primary or secondary disease?.
14. Reumatol Clin. 2012;8(5):287-91.
15. Greenspan BS, Dillehay G, Intenzo C, Lavely WC, O’Doherty M, Palestro CJ, Scheve W, Stabin MG, Sylvestros D, Tulchinsky M. SNM practice guideline for parathyroid scintigraphy 4.0. J Nucl Med Technol. 2012;40(2):111-8.
16. Moghadam RN, Amlelshahbaz AP, Namiranian N, Sobhan-Ardekani M, Emami-Meybodi M, Dehghan A et al. Comparative diagnostic performance of ultrasonography and 99mTc-sestamibi scintigraphy for parathyroid adenoma in primary hyperparathyroidism; systematic review and meta-analysis. Asian Pac J Cancer Prev. 2017;18(12):3195.
17. Bossert I, Chytiris S, Hodolic M, Croce L, Mansi L, Chiovato L, et al. PETC/CT with 18 F-Choline localizes hyperfunctioning parathyroid adenomas equally well in normocalcemic hyperparathyroidism as in overt hyperparathyroidism. J Endocrinol Invest. 2019;42:419-26.
18. Taillefer R, Boucher Y, Potvin C, Lambert R. Detection and localization of parathyroid adenomas in patients with hyperparathyroidism using a single radionuclide imaging procedure with technetium-99m-sestamibi (double-phase study). J Nucl Med. 1992;33(10):1801-7.
19. Taieb D, Hindie E, Grassetto G, Colletti PM, Rubello D. Parathyroid scintigraphy: when, how, and why? A concise systematic review. Clin Nucl Med . 2012;37(6):568-74.
20. Sandrock D, Merino MJ, Norton JA, Neumann RD. Ultrastructural histology correlates with results of thallium-201/technetium-99m parathyroid subtraction scintigraphy. J Nucl Med. 1993;34(1):24-9.
21. O’Doherty MJ, Kettle AG, Wells P, Collins RE, Coakley AJ. Parathyroid imaging with technetium-99m-sestamibi: preoperative localization and tissue uptake studies. J Nucl Med. 1992;33(3):313-8.
22. Hung GU, Wang SJ, Lin WY. Tc-99m MIBI parathyroid scintigraphy and intact parathyroid hormone levels in hyperparathyroidism. Clin Nucl Med. 2003;28(3):180-5.
23. Parikshak M, Castillo ED, Conrad MF, Talpos GB. Impact of hypercalcemia and parathyroid hormone level on the sensitivity of preoperative sestamibi scanning for primary hyperparathyroidism. Am Surg. 2003;69(5):393-9.
24. Koljević Marković A. Novi metod za kvantitativnu procenu promena u paraštitastoj žlezdi u primarnom hiperparatiroidizmu dinamskom scintiografijom sa dva radiofarmaka. Univerzitet u Beogradu, 2015.
25. Cordes M, Dworak O, Papadopoulos T, Coerper S, Kuwert T. MIBI scintigraphy of parathyroid adenomas: correlation with biochemical and histological markers. Endocr Res. 2018;43(3):141-8.
26. Dugonjić S, Cerović S, Janković Z, Ajdinović B. Correlation of subtraction parathyroid scintigraphy with weight, pathohistologic finding and oxyphil cell content of parathyroid glands in parathyroid hyperplasia. Vojnosanit Pregl. 2012;69(4):345-52.
27. Carpentier A, Jeannotte S, Verreault J, Lefebvre B, Bisson G, Mongeau CJ et al. Preoperative localization of parathyroid lesions in hyperparathyroidism: relationship between technetium-99m-MIBI uptake and oxyphil cell content. J Nucl Med. 1998;39(8):1441-4.
28. Silov G, Özdal A, Erdoğan Z, Turhal Ö, Karaman H. The relationship between technetium-99m-methoxyisobutyl isonitrile parathyroid scintigraphy and hormonal and biochemical markers in suspicion of primary hyperparathyroidism.Mol Imaging Radionucl Ther. 2013;22(1):8.
29. Silverberg SJ, Bilezikian JP. “Incipient” primary hyperparathyroidism: a “forme fruste” of an old disease J Clin Endocrinol Metab. 2003;88(11):5348-52.
30. Ozkaya M, Elboga U, Sahin E, Kalender E, Korkmaz H, Demir HD, Celen YZ, Erkılıç S, Gökalp A, Maralcan G. Evaluation of conventional imaging techniques on preoperative localization in primary hyperparathyroidism. Bosn J Basic Med Sci. 2015;15(1):61.
    

PDF: 06-Šekerović S. and Žeravica R. MD-Medical Data 2024;16(1) 043-047.pdf